DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs

Teratogenesis Carcinogenesis and Mutagenesis

Volumn 20, Issue 3, 2000, Pages 119-131

  Błasiak, Janusz ^a   Kowalik, Joanna ^a   Małecka Panas, Ewa ^b   Drzewoski, Józef ^b   Wojewódzka, Maria ^c  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

Author keywords

Cisplatin; Comet assay; Genotoxic effects of anticancer drugs; Oxoplatin; Se Pt conjugate (NH3)2Pt(SeO3)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXOPLATIN; PLATINUM DERIVATIVE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BINDING AFFINITY; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG DNA BINDING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LYMPHOCYTE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; TOXICITY TESTING;

ADULT; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CISPLATIN; COMET ASSAY; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DNA REPAIR; HUMANS; LYMPHOCYTES; MALE; SELENIUM COMPOUNDS;

EID: 0342656984     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6866(2000)20:3<119::AID-TCM3>3.0.CO;2-Z     Document Type: Article

References (39)

1. Abrams MJ, Murrer BA. Metal compounds in therapy and diagnosis. Science 1993;261:725-730.
2. Büning H, Altman J, Beck W, Zorbas H. Molecular interaction of DNA with bisplatinum(II) complexes having bis(vicinal 1,2-diamines) as ligand. Biochemistry 1997;36:11408-11418.
3. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. Cis-diammine-dichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 1987;47:3000-3004.
4. Bernal-Mendez E, Boudvillan M, Gonzalez-Vilchez F, Leng M. Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA. Biochemistry 1997; 36:7281-7287.
5. Sato PH, Rosenberg JM, Sato RL. Differences in the inhibition of translation by cisplatin, transplatin, and certain related compounds. Biochem Pharmacol 1996;52:1895-1902.
6. Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 1985;780:167-180.
7. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985;24:707-713.
8. Ferguson LR, Pearson AE. The clinical use of mutagenic anticancer drugs. Mutat Res 1996;355:1-12.
9. Novakova O, Vrana O, Kiseleva VI, Brabec V. DNA interactions of antitumor platinum(IV) complexes. Eur J Biochem 1995;228:616-624.
10. Johnson NP, Butour J-L, Viliani G, Wimmer FL, Defais M, Pierson V, Brabec V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog Clin Biochem Med 1989;10:1-24.
11. Combs GF, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998;79:179-192.
12. Roussyn I, Briviba K, Masumoto H, Sies H. Selenium-containing compounds protect DNA from single-strand breaks caused by peroxynitrite. Arch Biochem Biophys 1996;330:216-218.
13. Vermeulen NP, Baldew GS, Los G, McVie JG, De Goeij JJ. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds. Drug Metab Dispos 1993;21:30-36.
14. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumor activity. Br J Cancer 1988;58:38-41.
15. Baldew GS, Mol JGJ, de Kanter FJJ, van Baar B, de Goeij JJM, Vermeulen NPE. The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol 1991;41:1429-1437.
16. Baldew GS, McVie JG, van der Valk MA, Los G, de Goeij JJ, Vermeulen NP. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Cancer Res 1990;50:7031-7036.
17. Wachowicz B, Krajewski T, Olas B, Zbikowska HM. Effects of cisplatin and selenite on the level of thiols in pig blood platelets. J Physiol Pharmacol 1995;46:97-103.
18. L-trans) 1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat. Fund Appl Toxicol 1990;14:706-719.
19. 3)]; changes of blood platelet activation. Gen Physiol Biophys 1997;16:263-272.
20. Eastman A, Barry MA. The origins of DNA breaks: a consequence of DNA damage, DNA repair or apoptosis. Cancer Invest 1992;10:229-240.
21. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191.
22. McKelvey-Martin VJ, Green MHL, Schmezer P, Pool-Zobel BL, De Meo MP, Collins A. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res 1993;288:47-63.
23. Fairbairn DW, Olive PL, O'Neill KL. The comet assay: a comprehensive review. Mutat Res 1995;339:37-59.
24. Tice RR. The single cell gel/comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. In: Phillips DH, Venitt S, editors. Environmental mutagenesis. Oxford: BIOS Scientific; 1995. p 315-340.
25. Olive PL, Wlodek D, Durand RE, Banath JP. Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp Cell Res 1992;198:259-267.
26. Pfuhler S, Wolf HU. Detection of DNA-crosslinking agents with the alkaline comet assay. Environ Mol Mutagen 1996;27:196-201.
27. 3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes. J Inorg Biochem 1993;52:263-274.
28. Vrana O, Brabec V, Kleinwachter V. Polarographic studies on the conformation of some platinum complexes: relation to antitumor activity. Anti-Cancer Drug Design 1985;1:95-109.
29. Fichtinger-Schepman AMJ, van der Velde-Visser SD, van Dijk-Knijnenburg HCM, van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990;50:7887-7894.
30. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-3090.
31. Köberle B, Payne J, Grimaldi KA, Hartley JA, Masters JRW. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 1996;52:1729-1734.
32. Patrick SM, Henkels KM, Turchi JJ. High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA. Biochim Biophys Acta 1997;1354:279-290.
33. Barnhart KM, Bowden GT. Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer Lett 1985;29:101-105.
34. Kempf SR, Ivankovic S. Carcinogenic effect of cisplatin (cis-diamminedichloroplatinum(II), CDDP) in BD IX rats. J Cancer Res Clin Oncol 1986;111:133-136.
35. Leopold WR, Miller EC, Miller JA. Carcinogenicity of antitumor cis-platinum(II) coordination complexes in mouse and rat. Cancer Res 1979;39:913-918.
36. Morin-Faure J, Marcollet M. Immunocytochemical study of the action of cis-dichlorodiamino platinum on the human metaphase chromosome. Eur J Cell Biol 1983;30:913-918.
37. Bradley LJN, Yarema KJ, Lippard SJ, Essigmann JM. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 1993;32:982-988.
38. Fichtinger-Schepman AMJ. Genotoxicity as origin of the antitumor activity of platinum compounds. Arch Toxicol 1993;67:47-50.
39. Mansuri-Torshizi H, Mital R, Srivastava TS, Parekh H, Chitnis MP. Synthesis, characterization, and cytotoxic studies of alpha-diimine/1,2-diamine platinum(II) and palladium(II) complexes of selenite and tellurite and binding of some of these complexes to DNA. J Inorg Biochem 1991;44:239-247.